UBS AM
VERA icon

UBS AM’s Vera Therapeutics VERA Stock Holding History

UBS AM’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.4M Sell
195,706
-2,063
-1% -$76.9K ﹤0.01% 1342
2026
Q1 		$7.96M Sell
197,769
-5,184
-3% -$223K ﹤0.01% 1328
2025
Q4 		$10.3M Buy
202,953
+120,671
+147% +$4.29M ﹤0.01% 1119
2025
Q3 		$2.39M Sell
82,282
-70,816
-46% -$1.64M ﹤0.01% 1678
2025
Q2 		$3.61M Buy
153,098
+55,085
+56% +$1.24M ﹤0.01% 1861
2025
Q1 		$2.35M Buy
98,013
+17,907
+22% +$575K ﹤0.01% 1914
2024
Q4 		$3.39M Buy
80,106
+18,532
+30% +$821K ﹤0.01% 1792
2024
Q3 		$2.72M Buy
61,574
+6,494
+12% +$246K ﹤0.01% 1880
2024
Q2 		$1.99M Buy
55,080
+23,303
+73% +$924K ﹤0.01% 2002
2024
Q1 		$1.37M Buy
31,777
+10,460
+49% +$373K ﹤0.01% 1858
2023
Q4 		$328K Buy
+21,317
New +$271K ﹤0.01% 2409

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM's VERA Position: Q2 2026 in Review

UBS AM reduced its Vera Therapeutics (VERA) stake by 1% in Q2 2026, selling an estimated $76.9K and leaving 195,706 shares worth $8.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1342.

UBS AM first reported a position in VERA in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.3M in Q4 2025. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • UBS AM held 195,706 shares of Vera Therapeutics worth $8.4M as of Q2 2026.
  • UBS AM sold 2,063 Vera Therapeutics shares in Q2 2026, an estimated $76.9K.
  • Vera Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1342 holding.
  • UBS AM first reported a position in Vera Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • UBS AM's Vera Therapeutics position peaked at $10.3M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.